856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

by Quinn Deveraux, Heather Kinkead, Kyle Jones, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt, William Crago, Emily Rowell, Elisabeth Torretti
Published 2021-11-01

12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist

by Quinn Deveraux, Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Garrett Cyprus, Rajay Pandit, James Kalabus, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt
Published 2021-11-01